One-Time Spinal Gene Therapy Shows Favorable Safety in Children With SMA Who Stopped Other Treatments
In a 27-patient phase 3b trial, intrathecal onasemnogene abeparvovec was safe in treatment-experienced SMA patients, with motor function stable at one year.
Summary
Spinal muscular atrophy (SMA) is a genetic neuromuscular disease, and many patients now have prior experience with nusinersen or risdiplam. The phase 3b STRENGTH trial tested a one-time intrathecal gene therapy, onasemnogene abeparvovec (OAV101 IT), in 27 children and adolescents aged 2 to under 18 years who had stopped one of those treatments. Every participant had at least one adverse event, but most were mild, such as colds, fever and vomiting. Four (14.8%) had serious events, mostly respiratory infections, and none were judged treatment-related. No deaths or study withdrawals due to adverse events occurred. Motor function was stable over 52 weeks, with small average gains on the HFMSE and RULM scales. The safety profile matched that seen in treatment-naive patients. The study was single-arm and open-label, so efficacy conclusions are limited.
Detailed Summary
Spinal muscular atrophy results from loss of the SMN1 gene and progressive motor neuron degeneration. Three disease-modifying therapies exist: nusinersen, risdiplam and intravenous onasemnogene abeparvovec. The intravenous gene therapy is approved mainly for young, lighter children. Many older or heavier patients, and those who want to stop current treatment because of limited benefit, tolerability or access problems, have few options. Most people who might seek a new therapy in practice have already been treated, which makes data in this group important.
STRENGTH was a 52-week, phase 3b, single-arm, open-label study at 13 sites in nine countries. It enrolled 27 participants aged 2.4 to 17.7 years (mean 7.4) who had discontinued nusinersen (mean 4.3 years of use) or risdiplam (mean 3.0 years). Most had three SMN2 copies (85%). Each received one intrathecal dose of OAV101 (1.2 × 10^14 vector genomes) along with prophylactic prednisolone. The primary endpoint was safety. Secondary endpoints were change in the Hammersmith Functional Motor Scale–Expanded (HFMSE), the Revised Upper Limb Module (RULM) and caregiver experience (ACEND).
All participants had at least one adverse event, most commonly nasopharyngitis (55.6%), fever (51.9%) and vomiting (48.1%). Treatment-related events occurred in 48.1%, most often vomiting, headache and fever. Four participants (14.8%) had serious adverse events, mostly respiratory infections, and none were treatment-related. There were no deaths and no discontinuations due to adverse events. Adverse events of special interest included transient thrombocytopenia-related events (29.6%, such as nosebleeds and bruising), liver enzyme elevations (14.8%, resolved with prednisolone) and possible dorsal root ganglia toxicity signs (7.4%, mild paresthesia or sensory disturbance that resolved). No Hy's law cases, thrombotic microangiopathy, cardiac events or malignancies occurred.
On efficacy, mean HFMSE change at week 52 was +0.17 points (model-adjusted +1.05; 95% CI −0.21 to 2.32), and RULM change was +0.29 (adjusted +0.59). Caregiver scores were stable. Three of 24 participants gained a new motor milestone, including walking alone in two. Four participants began add-on SMA therapy, but excluding data after that point gave a nearly identical result (1.02).
The findings suggest OAV101 IT may be a one-time option for treatment-experienced patients, with a safety profile similar to that in treatment-naive patients. Stabilization, rather than marked improvement, is the realistic expectation in this group. Caveats include the small sample, the lack of a control group, open-label assessment, no hypothesis testing, and only one year of follow-up. Most participants were 6 years or older, and scoliosis and contractures were not excluded, which may have affected motor scores.
Key Findings
- All 27 participants had adverse events, mostly mild; 14.8% had serious events, none treatment-related, and there were no deaths or discontinuations.
- Liver enzyme elevations (14.8%) and thrombocytopenia-related events (29.6%) were manageable and resolved; no Hy's law cases occurred.
- Two participants (7.4%) had mild, transient signs possibly suggesting dorsal root ganglia toxicity, which resolved without treatment.
- Motor function was stable at 52 weeks: mean HFMSE change +0.17 and RULM +0.29, with high individual variability.
- Safety profile matched that in treatment-naive patients from STEER and STRONG; no new safety concerns emerged.
Methodology
STRENGTH was a 52-week, phase 3b, open-label, single-arm, multicenter trial in 27 participants aged 2 to <18 years with SMA who had discontinued nusinersen or risdiplam. Participants received one intrathecal OAV101 dose (1.2 × 10^14 vg) with prophylactic prednisolone. The primary endpoint was safety; secondary endpoints were HFMSE, RULM and caregiver experience, analyzed descriptively and with mixed models without hypothesis testing.
Study Limitations
The study was small, single-arm and open-label, with no matched control and no hypothesis testing, so efficacy cannot be established. Follow-up was only 52 weeks, most participants were aged 6 or older, scoliosis and contractures were not controlled for, and four participants started add-on SMA therapy during the study.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
